Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation Journal Article


Authors: Berman, E.; Little, C.; Gee, T.; O'Reilly, R.; Clarkson, B.
Article Title: Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation
Abstract: Background: Numerous reports suggest that allogeneic bone marrow transplantation prolongs the survival of adult patients with acute myelogenous leukemia (AML) in first remission. However, it is unclear how many such patients actually undergo this procedure.Methods: We reviewed the case records of 350 consecutive adult patients with AML treated with chemotherapy at a single institution from 1979 (when the policy of offering allogeneic transplantation to all such patients in first remission was introduced) through 1990. The criteria for exclusion before transplantation included age greater than 40 and, beginning in 1984, a diagnosis of acute promyelocytic leukemia.Results: One hundred forty-two patients (41 percent of the study population) were 40 years of age or younger. HLA testing was performed for 120 of these patients (85 percent). Sixty-seven patients (47 percent) had an HLA-identical sibling as a potential donor. One hundred three patients (73 percent) entered remission during treatment according to one of five chemotherapy protocols. Of the 52 patients who both entered remission and had an HLA match, 30 underwent transplantation while they were in first remission. These 30 patients constituted 21 percent of all study patients 40 years old or younger, 29 percent of all patients 40 or under who entered remission, 45 percent of all patients with an HLA match, 58 percent of all patients who had both a remission and a match, and 9 percent of all patients treated according to a protocol. Among patients with a match who did not undergo transplantation, those with primary refractory disease were the largest subgroup.Conclusions: These findings suggest that allogeneic bone marrow transplantation is performed in less than 60 percent of adult patients with AML who are potentially eligible for the procedure. (N Engl J Med 1992;326: 156–60.). © 1992, Massachusetts Medical Society. All rights reserved.
Keywords: adolescent; adult; school child; transplantation, homologous; acute granulocytic leukemia; major clinical study; statistics; allogenic bone marrow transplantation; age factors; remission; remission induction; bone marrow transplantation; hla typing; hla antigens; histocompatibility testing; leukemia, myelocytic, acute; human; priority journal; article; support, non-u.s. gov't
Journal Title: New England Journal of Medicine
Volume: 326
Issue: 3
ISSN: 0028-4793
Publisher: Massachusetts Medical Society  
Date Published: 1992-01-16
Start Page: 156
End Page: 160
Language: English
DOI: 10.1056/nejm199201163260303
PUBMED: 1727546
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ellin Berman
    173 Berman
  2. Bayard Clarkson
    220 Clarkson
  3. Richard O'Reilly
    748 O'Reilly
  4. Claudia   Little
    12 Little
  5. Timothy Gee
    46 Gee